Literature DB >> 22230093

BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions.

Victoria Del Gaizo Moore1, Anthony Letai.   

Abstract

Apoptosis is a form of programmed cell death that is controlled at the mitochondrion by the BCL-2 family of proteins. While much has been learned about the structure and function of these proteins over the past two decades, the important goal of predicting cell fate decisions in response to toxic stimuli is largely unrealized. BH3 profiling is a functional approach that can be used to predict cellular responses to stimuli based on measuring the response of mitochondria to perturbation by a panel of BH3 domain peptides. BH3 profiling has proven useful in identifying and understanding cellular dependence on individual anti-apoptotic proteins like BCL-2 or MCL-1. Consequently, it can also be used to predict cellular response to chemotherapy agents such as ABT-737 that target these individual proteins.
Copyright © 2012. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22230093      PMCID: PMC3770266          DOI: 10.1016/j.canlet.2011.12.021

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  34 in total

Review 1.  A view to a kill: ligands for Bcl-2 family proteins.

Authors:  Stacey E Rutledge; Jason W Chin; Alanna Schepartz
Journal:  Curr Opin Chem Biol       Date:  2002-08       Impact factor: 8.822

Review 2.  The Bcl2 family: regulators of the cellular life-or-death switch.

Authors:  Suzanne Cory; Jerry M Adams
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

3.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.

Authors:  Anthony Letai; Michael C Bassik; Loren D Walensky; Mia D Sorcinelli; Solly Weiler; Stanley J Korsmeyer
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

4.  Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death.

Authors:  M C Wei; W X Zong; E H Cheng; T Lindsten; V Panoutsakopoulou; A J Ross; K A Roth; G R MacGregor; C B Thompson; S J Korsmeyer
Journal:  Science       Date:  2001-04-27       Impact factor: 47.728

5.  BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak.

Authors:  W X Zong; T Lindsten; A J Ross; G R MacGregor; C B Thompson
Journal:  Genes Dev       Date:  2001-06-15       Impact factor: 11.361

6.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis.

Authors:  E H Cheng; M C Wei; S Weiler; R A Flavell; T W Mak; T Lindsten; S J Korsmeyer
Journal:  Mol Cell       Date:  2001-09       Impact factor: 17.970

7.  Antiapoptotic BCL-2 is required for maintenance of a model leukemia.

Authors:  Anthony Letai; Mia D Sorcinelli; Caroline Beard; Stanley J Korsmeyer
Journal:  Cancer Cell       Date:  2004-09       Impact factor: 31.743

8.  Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.

Authors:  Joseph T Opferman; Anthony Letai; Caroline Beard; Mia D Sorcinelli; Christy C Ong; Stanley J Korsmeyer
Journal:  Nature       Date:  2003-12-11       Impact factor: 49.962

Review 9.  Structural biology of the Bcl-2 family of proteins.

Authors:  Andrew M Petros; Edward T Olejniczak; Stephen W Fesik
Journal:  Biochim Biophys Acta       Date:  2004-03-01

Review 10.  A matter of life and death.

Authors:  Douglas R Green; Gerard I Evan
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

View more
  79 in total

1.  Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.

Authors:  Joan Montero; Jason Stephansky; Tianyu Cai; Gabriel K Griffin; Lucia Cabal-Hierro; Katsuhiro Togami; Leah J Hogdal; Ilene Galinsky; Elizabeth A Morgan; Jon C Aster; Matthew S Davids; Nicole R LeBoeuf; Richard M Stone; Marina Konopleva; Naveen Pemmaraju; Anthony Letai; Andrew A Lane
Journal:  Cancer Discov       Date:  2016-12-16       Impact factor: 39.397

2.  SORTCERY-A High-Throughput Method to Affinity Rank Peptide Ligands.

Authors:  Lothar Luther Reich; Sanjib Dutta; Amy E Keating
Journal:  J Mol Biol       Date:  2014-10-12       Impact factor: 5.469

3.  Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

Authors:  Paolo A Ascierto; Antonio M Grimaldi; Ana Carrizosa Anderson; Carlo Bifulco; Alistair Cochran; Claus Garbe; Alexander M Eggermont; Mark Faries; Soldano Ferrone; Jeffrey E Gershenwald; Thomas F Gajewski; Ruth Halaban; F Stephen Hodi; Richard Kefford; John M Kirkwood; James Larkin; Sancy Leachman; Michele Maio; Richard Marais; Giuseppe Masucci; Ignacio Melero; Giuseppe Palmieri; Igor Puzanov; Antoni Ribas; Yvonne Saenger; Bastian Schilling; Barbara Seliger; David Stroncek; Ryan Sullivan; Alessandro Testori; Ena Wang; Gennaro Ciliberto; Nicola Mozzillo; Francesco M Marincola; Magdalena Thurin
Journal:  J Transl Med       Date:  2014-10-28       Impact factor: 5.531

Review 4.  Survival control of malignant lymphocytes by anti-apoptotic MCL-1.

Authors:  Y Fernández-Marrero; S Spinner; T Kaufmann; P J Jost
Journal:  Leukemia       Date:  2016-08-01       Impact factor: 11.528

5.  CD27 Promotes CD4+ Effector T Cell Survival in Response to Tissue Self-Antigen.

Authors:  Kelly A Remedios; Lauren Meyer; Bahar Zirak; Mariela L Pauli; Hong-An Truong; Devi Boda; Michael D Rosenblum
Journal:  J Immunol       Date:  2019-06-17       Impact factor: 5.422

6.  BH3 Profiling Reveals Selectivity by Herpesviruses for Specific Bcl-2 Proteins To Mediate Survival of Latently Infected Cells.

Authors:  Olesea Cojohari; Christine M Burrer; Megan A Peppenelli; Fardokht A Abulwerdi; Zaneta Nikolovska-Coleska; Gary C Chan
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

7.  Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.

Authors:  Stephen E Kurtz; Christopher A Eide; Andy Kaempf; Vishesh Khanna; Samantha L Savage; Angela Rofelty; Isabel English; Hibery Ho; Ravi Pandya; William J Bolosky; Hoifung Poon; Michael W Deininger; Robert Collins; Ronan T Swords; Justin Watts; Daniel A Pollyea; Bruno C Medeiros; Elie Traer; Cristina E Tognon; Motomi Mori; Brian J Druker; Jeffrey W Tyner
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-07       Impact factor: 11.205

8.  Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Authors:  Marina Konopleva; Daniel A Pollyea; Jalaja Potluri; Brenda Chyla; Leah Hogdal; Todd Busman; Evelyn McKeegan; Ahmed Hamed Salem; Ming Zhu; Justin L Ricker; William Blum; Courtney D DiNardo; Tapan Kadia; Martin Dunbar; Rachel Kirby; Nancy Falotico; Joel Leverson; Rod Humerickhouse; Mack Mabry; Richard Stone; Hagop Kantarjian; Anthony Letai
Journal:  Cancer Discov       Date:  2016-08-12       Impact factor: 39.397

9.  Host-based Prophylaxis Successfully Targets Liver Stage Malaria Parasites.

Authors:  Alyse N Douglass; Heather S Kain; Marian Abdullahi; Nadia Arang; Laura S Austin; Sebastian A Mikolajczak; Zachary P Billman; Jen C C Hume; Sean C Murphy; Stefan H I Kappe; Alexis Kaushansky
Journal:  Mol Ther       Date:  2015-02-04       Impact factor: 11.454

10.  KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.

Authors:  Julia Etchin; Takaomi Sanda; Marc R Mansour; Alex Kentsis; Joan Montero; Bonnie T Le; Amanda L Christie; Dilara McCauley; Scott J Rodig; Michael Kauffman; Sharon Shacham; Richard Stone; Anthony Letai; Andrew L Kung; A Thomas Look
Journal:  Br J Haematol       Date:  2013-02-04       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.